Navigation Links
EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024
Date:12/29/2015

NEW YORK, Dec. 29, 2015 /PRNewswire/ -- 

Summary

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

- The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
- The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MRSA market.
- Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
- Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.
Read the full report: http://www.reportlinker.com/p03411259-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
2. EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2023
3. EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
4. EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023
5. EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023
6. EpiCast Report: Sepsis - Epidemiology Forecast to 2023
7. EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024
8. EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024
9. Report: Upgrading Medicaid Drug Benefits Could Save Pennsylvania $896 Million
10. BioMEMS 2013 Report: Microsystem Device Market for Healthcare Applications
11. New Oral Anticoagulants Markets Research Report: New Anticoagulants and their Manufacturers Covered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2018)... ... October 17, 2018 , ... ... recently published a new technique documenting the use of placental based growth factors ... According to Dr. Holtzclaw, “At our DIA Dental Implant Center locations in ...
(Date:10/17/2018)... ... , ... Sri Lanka Export Development Board, the country’s apex body ... Authority are organising pavilions at SIAL International Food Fair to be held in Paris ... largest food innovation exhibition, SIAL 2018 international Food Fair is estimated to draw in ...
(Date:10/17/2018)... , ... October 17, 2018 , ... ... for Health Care (ACHC) President and CEO José Domingos to its board of ... José Domingos to our Board of Directors, whose broad and varied stakeholder composition ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University ... Academy of Integrative Health and Medicine’s (AIHM) Visionary Award for his passionate efforts ... Dr. Pizzorno was selected as AIHM’s recipient of the Visionary Award due to ...
(Date:10/16/2018)... ... October 16, 2018 , ... Sheba Vine, JD, CPCO, Vice ... law, writes frequently on employment law matters and has contributed articles to Compliance ... Health Care Compliance Professional's Manual titled “Navigating the Evolving Marijuana Landscape” to serve ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... company founded by patient-survivors, and The Avoca Group, Inc., a life sciences ... execution process, today announced its mutual collaboration that will make Avoca’s industry ...
(Date:10/13/2018)... ... 2018 , ... This World Food Day – Tuesday, October 16 – ... hunger by 2030 by breaking a GUINNESS WORLD RECORDS title with volunteers around the ... locations and five international locations together to break the GUINNESS WORLD RECORDS title for ...
(Date:10/11/2018)... , ... October 11, 2018 , ... ... a diverse range of healthcare organizations nationwide, announced today the launch of its ... on the Company’s portfolio of services while offering a more comprehensive understanding of ...
Breaking Medicine News(10 mins):